13F reference period
Q3 2026
Security Snapshot
BIO-RAD LABORATORIES, INC. - CL A (BIO) Institutional Ownership
CUSIP: 090572207
13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026
Institutions Reporting
241
Shares (Excl. Options)
11.44M
Full value: 11,442,201 · shares · 30 Sep 2026Price
$377.71
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / CL A
- Symbol
- BIO on NYSE
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 11,442,201
- Total 13F value
- $4,322,241,543
- Portfolio coverage rank
- 0.01%
- Share change
- -286,135
- Value change
- -$90,117,588
- Number of holders
- 241
- Shares outstanding
- 5,071,025
- SEC-reported price per share
- $363.73
- Insider filing price
- $363.73
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- BIO - BIO-RAD LABORATORIES, INC. - CL A is tracked under CUSIP 090572207.
- 241 institutions reported positions in Q3 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 399 to 241 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$5.7B
Full value: $5,698,605,998 · USD · 30 Jun 2026.$4.32B
Full value: $4,322,241,543 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 241 institutions filings for Q3 2026.
Security key
090572207
13F reference period
Q3 2026
13F holders
241
13D/G owners
5
CIK / CUSIP context first
Open Q3 2026 holders
BIO full holder history
BIO-RAD LABORATORIES, INC. SEC filings
BIO-RAD LABORATORIES, INC. company facts
BIO-RAD LABORATORIES, INC. insider transactions
BIO-RAD LABORATORIES, INC. 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 090572207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
BIO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| SCHWARTZ NORMAN D | 97% | $1,382,052,897 | 4,929,036 | Norman D. Schwartz | 25 Sep 2025 | |||
| SCHWARTZ ALICE N | 12% | $659,303,856 | 2,732,073 | Alice N. Schwartz | 01 May 2025 | |||
| First Eagle Investment Management, LLC | 11% | +14% | $657,060,173 | +$60,827,513 | 2,528,321 | +10% | First Eagle Investment Management, LLC | 30 Jun 2025 |
| VANGUARD GROUP INC | 8.4% | $462,850,693 | 1,907,640 | The Vanguard Group - 23-1945930 | 30 Sep 2024 | |||
| BlackRock, Inc. | 7.4% | $453,705,832 | 1,618,123 | BlackRock, Inc. | 30 Sep 2025 |
As of 30 Sep 2026,
241
institutional investors reported holding
shares of
BIO-RAD LABORATORIES, INC. - CL A (BIO).
This represents
226%
of the company’s total
outstanding shares.
11.44M
Full value: 11,442,201 · shares · 30 Sep 20265.07M
Full value: 5,071,025 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
205%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| First Eagle Investment Management, LLC | 48% | 2,455,580 | -5.8% | 1.5% | $927,497,228 |
| DIMENSIONAL FUND ADVISORS LP | 17% | 885,977 | -6.2% | 0.06% | $334,645,742 |
| VANGUARD CAPITAL MANAGEMENT LLC | 16% | 827,202 | +0.03% | 0.01% | $312,442,467 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 16% | 811,564 | -0.57% | 0.01% | $306,535,838 |
| ARIEL INVESTMENTS, LLC | 16% | 789,341 | -3.4% | 3.1% | $298,141,989 |
| Capital Research Global Investors | 12% | 596,244 | +34% | 0.03% | $225,207,321 |
| STATE STREET CORP | 11% | 575,209 | +0.6% | 0.01% | $217,262,191 |
| EARNEST PARTNERS LLC | 11% | 567,815 | -2.2% | 0.84% | $214,469,404 |
| NEUBERGER BERMAN GROUP LLC | 7.8% | 396,150 | +254% | 0.1% | $149,643,754 |
| Capital World Investors | 7.1% | 359,300 | -22% | 0.02% | $135,711,203 |
| GEODE CAPITAL MANAGEMENT, LLC | 6.8% | 342,553 | -1.4% | 0.01% | $129,418,388 |
| MORGAN STANLEY | 6.1% | 307,206 | +61% | 0.01% | $116,035,426 |
| First Pacific Advisors, LP | 5.3% | 269,082 | -33% | 1.2% | $101,634,962 |
| FRANKLIN TEMPLETON INC | 3.8% | 191,954 | -0.89% | 0.02% | $72,940,601 |
| Assenagon Asset Management S.A. | 2.9% | 147,506 | -37% | 0.06% | $55,714,491 |
| VANGUARD FIDUCIARY TRUST CO | 2.3% | 115,740 | +1.2% | 0.01% | $43,716,155 |
| Fisher Asset Management, LLC | 2.3% | 114,719 | -1.9% | 0.01% | $43,330,513 |
| Boston Trust Walden Corp | 2.1% | 105,556 | -5% | 0.32% | $39,869,556 |
| Hosking Partners LLP | 1.9% | 95,472 | +1.1% | 1.3% | $36,060,729 |
| EXCHANGE TRADED CONCEPTS, LLC | 1.7% | 87,691 | +22% | 0.15% | $33,121,768 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 1.7% | 86,848 | -15% | 0.03% | $32,803,358 |
| MARSHALL WACE, LLP | 1.3% | 67,994 | +258% | 0.02% | $25,682,014 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.3% | 66,578 | +387% | 0.01% | $25,147,176 |
| Arnhold LLC | 1.1% | 55,568 | 1.5% | $20,988,589 | |
| Tikvah Management LLC | 1.1% | 53,904 | -21% | 6.3% | $20,360,080 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 11,442,201 | $4,322,241,543 | -$90,117,588 | $377.71 | 241 |
| 2026 Q2 | 19,408,689 | $5,698,605,998 | -$156,047,532 | $293.61 | 399 |
| 2026 Q1 | 19,993,059 | $5,571,387,127 | +$145,017,022 | $278.75 | 395 |
| 2025 Q4 | 19,395,317 | $5,876,856,221 | -$33,433,698 | $302.99 | 396 |
| 2025 Q3 | 19,459,016 | $5,457,813,449 | +$102,667,994 | $280.39 | 392 |
| 2025 Q2 | 19,201,217 | $4,634,744,932 | +$3,469,914 | $241.32 | 380 |
| 2025 Q1 | 19,188,664 | $4,671,911,959 | +$52,969,583 | $243.56 | 429 |
| 2024 Q4 | 18,778,253 | $6,169,336,505 | -$215,682,627 | $328.51 | 450 |
| 2024 Q3 | 19,370,183 | $6,481,921,085 | -$218,781,622 | $334.58 | 433 |
| 2024 Q2 | 19,799,636 | $5,407,155,613 | +$314,233,620 | $273.11 | 428 |
| 2024 Q1 | 18,483,713 | $6,388,531,345 | +$32,714,858 | $345.87 | 456 |
| 2023 Q4 | 18,529,807 | $5,981,150,118 | -$116,305,124 | $322.89 | 479 |
| 2023 Q3 | 18,786,490 | $6,730,924,381 | -$58,698,141 | $358.45 | 466 |
| 2023 Q2 | 18,297,158 | $6,935,982,346 | -$192,100,378 | $379.12 | 463 |
| 2023 Q1 | 19,221,018 | $9,200,944,144 | +$12,069,903 | $479.02 | 499 |
| 2022 Q4 | 19,259,738 | $8,110,380,673 | -$117,736,871 | $420.49 | 467 |
| 2022 Q3 | 19,487,538 | $8,135,809,192 | +$113,970,897 | $417.14 | 471 |
| 2022 Q2 | 19,114,362 | $9,462,174,468 | +$34,485,329 | $495.00 | 489 |
| 2022 Q1 | 19,167,385 | $10,796,615,316 | -$34,402,167 | $563.23 | 505 |
| 2021 Q4 | 19,102,716 | $14,417,922,909 | -$389,707,592 | $755.57 | 521 |
| 2021 Q3 | 19,387,789 | $14,451,450,076 | +$60,848,148 | $745.95 | 500 |
| 2021 Q2 | 19,381,230 | $12,476,219,166 | -$119,629,052 | $644.29 | 496 |
| 2021 Q1 | 19,617,764 | $11,195,376,908 | -$8,883,384 | $571.17 | 483 |
| 2020 Q4 | 19,657,768 | $11,449,028,308 | +$302,277,766 | $582.94 | 483 |
| 2020 Q3 | 19,264,413 | $9,927,181,928 | +$28,169,224 | $515.46 | 471 |